A Study Evaluating the Safety and Clinical Activity of HC... | NCT00367887

ID	Type	Description	Link
B3381001

Official Title

A Phase 2, Randomized, Open-Label Study Of The Safety, Antiviral Activity, And Pharmacokinetics Of HCV-796 Administered In Combination With Peginterferon Alfa 2B (Peg-Intron) Plus Ribavirin (Rebetol) Versus Peg-Intron Plus Rebetol In Subjects With Hepatitis C Virus Genotype 1 Infection

Status Module

Name	Class
ViroPharma	INDUSTRY

Oversight Module

Description Module

Design Module

Interventional Study Design

Biospecimen

No data available

No data is available for this block.

Arms/Interventions Module

Arm Groups

Label	Type	Intervention Names
1	Active Comparator	Drug: Peg-Intron Drug: REBETOL
2	Active Comparator	Drug: HCV 796 Drug: Peg-Intron Drug: REBETOL
3	Active Comparator	Drug: HCV 796 Drug: Peg-Intron Drug: REBETOL

Name	Type	Description	Arm Group Labels	Other Names
Peg-Intron	Drug	SC injection, weight based dosing, weekly, 48 weeks	1

Outcomes Module

Measure	Description	Time Frame
Hepatitis C Virus (HCV) RNA concentrations in the blood.		72 weeks

Eligibility Module

Contacts/Locations Module

Name	Affiliation	Role
Pfizer CT.gov Call Center	Pfizer	Study Director

Facility	Status	City	State	ZIP	Country	Contacts
Pfizer Investigational Site		Anaheim	California	92801	United States
Pfizer Investigational Site

References Module

Label	URL
To obtain contact information for a study center near you, click here.	View source

Ancestor Terms

ID	Term
D000086982	Blood-Borne Infections
D003141	Communicable Diseases
D007239	Infections
D006525	Hepatitis, Viral, Human
D014777	Virus Diseases
D018178	Flaviviridae Infections
D012327	RNA Virus Infections
D006505	Hepatitis
D008107	Liver Diseases
D004066	Digestive System Diseases

ID	Term
D012263	Ribonucleosides
D009705	Nucleosides
D009706	Nucleic Acids, Nucleotides, and Nucleosides